Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference May 14, 2025 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announ

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy May 13, 2025 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a Phase 3 clinical trial comparing aficamten as monotherapy to the standard of care beta blocker metoprolol as monotherapy i

May 13, 2025 -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monito

May 13, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercially available for t

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 May 13, 2025 -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced th

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention - May 13, 2025 -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and

– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK (NCT06839235) – Preclinical data demonstrate highly specific and durable editing of HAO1 with long-lasting reduction of urinary oxalate levels out to one-year post-single dose administration of ABO-101 – Non-human primate studies confirm preclinical efficacy and tolerability of ABO-101 with efficient editing of HAO1, red

Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase 1/2 trial in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) Phase 1 clinical study of RPT1G in healthy volunteers concludes in May 2025 May 13, 2025 -- Remedy Plan Therapeutics (Remedy Plan), a privately-held, clinical-stage pharmaceutical company developi

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value May 13, 2025 -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncolo

- Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 May 13, 2025 -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced the presentation of new preclinical data in two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025 in New Orleans, LA. The two poster presentations include data that